Microplastics (MPs) and nanoplastics (NPs) have emerged as pervasive environmental contaminants with increasing evidence of human exposure and biological accumulation. Recent studies have confirmed their presence in multiple human reproductive tissues and fluids, including semen, testicular tissue, ovarian follicular fluid, cervicovaginal secretions, placenta, and breast milk, raising concerns regarding their potential implications for reproductive health. Beyond their widespread distribution, MPs have been shown in experimental studies to interact with cellular and molecular processes, including oxidative stress, inflammatory responses, mitochondrial dysfunction, and DNA damage, which are pathways commonly implicated in carcinogenesis. This review provides a comprehensive and critical synthesis of current evidence linking microplastic exposure to reproductive cancers, including prostate, testicular, ovarian, endometrial, cervical, and vaginal malignancies. Available mechanistic studies suggest that MPs may influence cancer-related biological processes through dysregulation of programmed cell death, genotoxicity, endocrine disruption, and modulation of signaling pathways such as PI3K/AKT and MAPK. Experimental findings also indicate that MPs may alter the tumor microenvironment and affect cellular behaviors associated with proliferation, migration, and invasion. However, the majority of current evidence is derived from in vitro studies, animal models, and indirect mechanistic observations, while direct epidemiological evidence in humans remain limited. Furthermore, methodological heterogeneity in microplastic detection and characterization complicates comparisons across studies and hinders causal inference. Overall, current evidence supports the biological plausibility of an association between microplastic exposure and reproductive cancer-related processes, while highlighting the need for standardized methodologies and well-designed longitudinal human studies to clarify potential health risks.
B. Rais, A. Vafa, Faten F. Bin Dayel et al.· Journal of Xenobiotics· 0 citations
Diabetes mellitus characterizes a key universal health concern associated with severe metabolic complications. In this current study, a biogenic approach was employed to synthesize silver nanoparticles (AgNPs) using rifabutin as both a reducing and stabilizing agent. The resulting Rifabutin‐AgNPs were thoroughly characterized by UV–vis spectroscopy, x‐ray diffraction (XRD), scanning electron microscopy (SEM), and Fourier‐transform infrared spectroscopy (FTIR), confirming their crystalline nature and functional group interactions responsible for nanoparticle stabilization. The antidiabetic potential of the synthesized Rifabutin‐AgNPs was evaluated in streptozotocin (STZ)‐induced diabetic rats. Oral administration of Rifabutin‐AgNPs (5 and 10 mg/kg) for 14 days produced a significant, dose‐dependent reduction in blood glucose levels, improved serum lipid profiles, and normalized hepatic transaminase (SGOT and SGPT) activities compared with untreated diabetic controls. The superior therapeutic efficacy of Rifabutin‐AgNPs over pure rifabutin highlights the potential of this green synthesized nanoformulation as an efficient platform for diabetes management at the chemical biological interface.
Ayushi Maurya, Mohd Ibrahim Khan, S. Ansari et al.· Chemistry and Biodiversity· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.